乌鸦传媒

<乌鸦传媒 class="page-title">Meeting Coverage

ASH Expert Roundtable: DLBCL

<乌鸦传媒 class="page-description">Expert Roundtable from the American Society of Hematology
Novel Combination Active in Large B-Cell Lymphoma, Even After CAR-T

But where mosunetuzumab/polatuzumab vedotin would fit among available options remains a question

image
<乌鸦传媒 class="section_title">Latest ASH Expert Roundtable: DLBCL Meeting Coverage
Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients

Our panel discusses findings from the ZUMA-12 study and the ZUMA-7 study

January 4, 2024
Chemo-Free Quadruplet Promising as Initial Treatment in DLBCL

Approach could allow for a response-adapted reduction of CHOP

December 27, 2023
Positive Results for Odronextamab in Relapsed/Refractory DLBCL

But experts aren't sure where it would fit in with currently approved bispecifics

December 20, 2023
Liso-Cel Improves Outcomes in Relapsed/Refractory Large B-Cell Lymphoma

Ian Flinn, MD, leads a roundtable discussion with Loretta Nastoupil, MD, and Amitkumar Mehta, MD

January 19, 2022
CAR-T Trial Fails in Aggressive Large B-Cell Lymphoma

Ian Flinn, MD, leads a roundtable discussion with Loretta Nastoupil, MD, and Amitkumar Mehta, MD

January 12, 2022
Is Second-Line Axi-Cel the New Standard in Aggressive B-Cell Lymphoma?

Ian Flinn, MD, leads a roundtable discussion with Loretta Nastoupil, MD, and Amitkumar Mehta, MD

December 29, 2021
Finally, a Positive Study in First-Line DLBCL Treatment. What Will it Mean?

Ian Flinn, MD, leads a discussion on POLARIX with Loretta Nastoupil, MD, and Amitkumar Mehta, MD

December 22, 2021
<乌鸦传媒 class="section_title"> Latest Oncology/Hematology Meeting Coverage